2 results
Approved WMORecruiting
To test the hypothesis that LY3314814, administered orally at doses of 20 and 50 mg daily for 78 weeks, will slow the decline of AD ascompared with placebo in patients with mild AD dementia.
Approved WMORecruiting
To establish the efficacy of targeted LV lead delivery in a sufficiently powered randomized, multicentre study. Efficacy is determined based on the distance of the LV-lead to the targeted cardiac segment, as determined pre-implantation by CARTBox.